The European Patent Office has granted BRAIN Biotech a substance patent for its CRISPR-BMC nuclease, designated EP4301852 B1, marking a significant development in genome-editing tools with broad industrial applications. This patent protection, effective since March 18, 2026, across European Unitary Patent countries, Great Britain, and Switzerland, provides the company with freedom to utilize the technology in research and customer projects while opening substantial commercial potential through expanded licensing activities.
The newly patented CRISPR-BMC technology represents a novel family of nucleases that generate efficient double-strand breaks at specific genomic locations in both prokaryotic and eukaryotic cells. These precise breaks enable targeted genetic modifications that can alter organism properties, with applications spanning bacteria, yeasts, fungi, plants, and mammalian cells. The technology complements BRAIN Biotech's existing CRISPR-BEC nucleases, both developed through the company's BRAINBioIncubator research division.
From an industrial perspective, this development matters because it offers a tool for optimizing microbial production strains used in manufacturing biomolecules like enzymes, proteins, and small molecules. BRAIN Biotech specifically applies the technology to strains including E. coli, Bacillus, Pichia, and Aspergillus, potentially making bioprocesses more economical. As CEO Adriaan Moelker noted, "Our technology, which is based on these nucleases, helps make manufacturing processes that utilize microorganisms more cost-effective."
The implications extend beyond BRAIN Biotech's internal operations to various industries that could license the technology. The company has already granted licenses to companies in different fields and plans to expand these activities. This broad applicability stems from the technology's versatility across organism types and its precision, which Alexander Pelzer, Head of R&D at BRAIN Biotech Zwingenberg, says "allows us to further accelerate the development of our own production organisms and strain development for our customers thanks to the speed and precision it offers."
For the biotechnology sector, this patent represents another proprietary CRISPR system entering the competitive landscape, potentially offering advantages in specific applications or organisms. The technology's development draws on decades of molecular biology and microbiology experience at BRAIN Biotech, which operates fermentation facilities in the UK and additional production sites in continental Europe and the US. While the patent is currently effective in European jurisdictions, it remains pending in other key markets including the United States and Japan, with protection being sought for additional nucleases within the BMC family.
The broader significance lies in how this technology could enable more sustainable and efficient industrial processes through biological solutions. As industries seek to reduce environmental impact and production costs, precise genome-editing tools like CRISPR-BMC could facilitate the development of optimized microorganisms for various applications. The company's business model, offering strain optimization services for customer production strains, positions this technology as a practical solution rather than merely a research tool. For more information about BRAIN Biotech's broader operations, visit https://www.brain-biotech-group.com.
